⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15518498 | 0.92 | — | — | |
| SCHEMBL21662427 | 0.90 | TSHR (0.55) | — | |
| SCHEMBL2911142 | 0.83 | — | — | |
| SCHEMBL9178365 | 0.78 | ALDH1A1 (0.52) | — | |
| SCHEMBL737741 | 0.77 | TSHR (0.57) | — | |
| SCHEMBL1291112 | 0.77 | ALDH1A1 (0.52) | — | |
| SCHEMBL891903 | 0.76 | — | — | |
| SCHEMBL144980 | 0.76 | — | — | |
| SCHEMBL10033122 | 0.75 | — | — | |
| Formaldehyde SCHEMBL27582133 | 0.75 | ALDH1A1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12163124-B2 | Method for gene editing | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3362564-B1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | AQUINNAH PHARMACEUTICALS INC (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019118806-A1 | NON-VIRAL PRODUCTION AND DELIVERY OF GENES | SOLID BIOSCIENCES INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20190142860-A1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-16 | — | — | US | disclosed |
| EP-3362564-A1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | Aquinnah Pharmaceuticals Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066657-A1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | AQUINNAH PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-2823821-B1 | ANTIBODY SPECIFICALLY BINDING TO DIGOXIGENIN | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-9574016-B2 | Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent | HOFFMANN-LA ROCHE INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160009823-A1 | COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT | HOFFMANN-LA ROCHE INC. (US) | 2016-01-14 | — | — | US | disclosed |
| EP-2451480-B1 | A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2451479-B1 | BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES | HOFFMANN LA ROCHE (CH) | 2015-04-01 | — | — | EP | disclosed |
| EP-2823821-A1 | Antibody specifically binding to digoxigenin | F. Hoffmann-La Roche AG (CH) | 2015-01-14 | — | — | EP | disclosed |
| US-8907069-B2 | Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent | HOFFMANN-LA ROCHE INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20120282280-A1 | BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120269723-A1 | COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-25 | — | — | US | disclosed |
| EP-2451480-A1 | A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT | F. Hoffmann-La Roche AG (CH) | 2012-05-16 | — | — | EP | disclosed |
| EP-2451479-A1 | BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES | F. Hoffmann-La Roche AG (CH) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003557-A1 | A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011003780-A1 | BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-13 | — | — | WO | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |